Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs laser photocoagulation long-term follow-up in ROP
NCT04015180Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2020
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 24
01
Overview
A Phase 3 trial of aflibercept in retinopathy of prematurity (ROP), sponsored by Bayer. Started Mar 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT04015180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015180.